Announcement
The ECMC Programme Office has successfully recruited to four new roles: Student Combinations Alliance Assistant, Project Officer, Project Manager (Workforce) and Project Manager (Network Capabilities).
Cancer Research UK's Centre for Drug Development is pleased to announce the successful conclusion of its tender for biomarker delivery for early phase clinical trial work.
Following on from the success of the first workshop in London earlier this year, CRUK’s Centre for Drug Development (CDD), in collaboration with the ECMC Programme Office, hosted a second workshop, ‘Delivery of Early Phase Trials: How can we excel?’, in Newcastle on 22 June 2017.
Newcastle University is seeking to recruit a new Clinical Chair in Molecular Pathology. This exciting opportunity will be advertised in September 2017. We will be looking for a talented and highly motivated individual to spearhead our programme in Molecular Pathology, working closely with the Newcastle EPSRC/MRC Molecular Pathology Node one of six awarded across the UK.
The Public and Patient Involvement team at Cancer Research UK has developed a new Patient and Public Involvement (PPI) in Research Toolkit for the research community. This toolkit is packed with resources, information, and guidance to support PPI in cancer research.
As part of the new quinquennium, Cardiff ECMC has begun setting up an ECMC Haematology network. The main purpose of this group is to promote haematology activities within the ECMC and consider ways it can work collectively as a group.
The ECMC Translational Science subgroup of QATS (Quality Assurance & Translational Science group) organised its very first conference titled ‘Opportunities and challenges with emerging biomarker technologies and their application in early phase trials’ on 20 March. The one-day event was held at the ICR in Sutton and organised by Karen Swales, Senior Scientific Officer, ICR CRUK Therapeutics Unit and chair of the Translational Science subgroup.
Both the CRUK Stratified Medicine Programme (SMP2) and the National Lung Matrix Trial (NLMT) are at a crucial phase of trial delivery.
SMP2 and NLMT are open to recruitment at 17 and 16 ECMCs respectively. Both study teams are collaborating to set up three new sites (Liverpool, Maidstone and Devon and Exeter) as part of a phased approach that aims to introduce several new sites across the country.
The development of new treatments for pancreatic cancer is set to be transformed by a £10m investment by Cancer Research UK into a network of clinical trials, aiming to find the right trial for the right patient.
The UK's only current trial dedicated to the treatment of myelomonocytic leukaemia (CMML) has recruited its first patient. The Phase II MONOCLE study has opened at the Institute of Cancer & Genetics at Cardiff University, and has received funding support from the Cardiff ECMC.